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Insulin is one of the major metabolic hormones regulating glucose homeostasis in the organism and a key growth
factor for normal and neoplastic cells. Work conducted primarily over the past 3 decades has unravelled the
presence of insulin in human breast cancer tissues and, more recently, in human non-small cell lung carcinomas
(NSCLC). These findings have suggested that intracellular insulin is involved in the development of these highly
prevalent human tumors. A potential mechanism for such involvement is insulin’s binding and inactivation of the
retinoblastoma tumor suppressor protein (RB) which in turn is likely controlled by insulin-degrading enzyme (IDE).
This model and its supporting data are collectively covered in this survey in order to provide further insight into
insulin-driven oncogenesis and its reversal through future anticancer therapeutics.
Introduction
It has meanwhile been nearly a century since insulin’s
stimulatory effects on cell proliferation and tissue
growth have been studied [1-3]. Thereby, insulin’s
growth-promoting actions have mainly been attributed
to its complex formation with the insulin receptor
located on the surface of various cells and cloned in the
mid-1980s [4] along with the second messenger cas-
cades initiated by such heterodimerization [5].
However, historically preceding and coinciding with
this model on an extracellular insulin activity, there
have also been reports of direct - i.e. (non-insulin recep-
tor-mediated and) intracellular- insulin effects at the
level of the cell nucleus [6] and, moreover, on RNA and
protein synthesis by intracellular insulin [7] as well as
on the transcription of immediate-early genes by intra-
nuclear insulin [8].
In the early 1990s, this conceptual framework on an
intracellular localization and action of insulin was
expanded by a novel proposal according to which insu-
lin may physically interact with the (mainly nuclear)
retinoblastoma tumor suppressor protein (RB) and
thereby, similar to RB-binding viral oncoproteins, inacti-
vate RB and thus promote cell proliferation [9] which
was subsequently validated experimentally [10-13], pri-
marily in human tumor cell culture models [11-13]. The
present review will focus on delineating this potential
intracellular signal transduction pathway for insulin,
thereby taking primarily into account human cell line
and tissue studies as well as its possible inhibition by
anticancer drug candidates directly targeting this mole-
cular avenue.
Dual mode of insulin signalling
As a result of an insulin-insulin receptor interaction in
the presence of low nanomolar insulin concentrations, a
second messenger cascade is activated among which the
intracellular enzyme phosphatidylinositol 3-kinase (PI 3-
kinase) is a major intermediary molecule [14]. Further
downstream from PI 3-kinase, this cascade leads to Ras
activation and, ultimately, to retinoblastoma protein
inactivation through the latter’s hyperphosphorylation
[15], the outcome of this cascade being cell cycle pro-
gression and increased cell proliferation.
In addition to this signalling cascade initiated by insu-
lin at the level of the cell membrane, it has become
increasingly apparent over the past three and a half dec-
ades that insulin could also act as its own messenger
(i.e. without the mediation of other molecules) in order
to directly promote cell growth, specifically insulin
molecules that are located intracellularly.
The main support for such a possibility comes from
studies conducted on human cancer tissue specimens
and revealing the presence of intratumoral insulin
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only the detection of cytoplasmic insulin, but also of
nuclear insulin [17]. These investigations indicated the
possibility that such intracellular insulin may contribute
to the pathogenesis of these neoplasias.
A potential mechanism for such intracellular insulin-
driven tumor growth is the insulin-RB complex forma-
tion that, so far, has been experimentally demonstrated
in several human carcinoma-derived cell lines [11-13].
This intracellular complex would be expected to occur
primarily in the nuclei of such tumors, but a cytosolic
presence of this heterodimer is also conceivable both of
which subcellular localizations ought to be addressed in
future studies, e.g. by employing lysates of primary
tumors obtained from cancer patients.
Furthermore, the probability for this interaction should
be higher in neoplastic cells which equally display a dys-
function of insulin-degrading enzyme (IDE) or, respec-
tively, insulysin in the light of previous data showing that
an inactivation of IDE leads to an increase in the nuclear
localization of insulin [20]. In this context, it is interest-
ing to note that the same compound (1,10-phenanthro-
line) used to block IDE activity [20] has also been shown
to decrease the formation of the tumor-suppressive wild-
type conformation of the p53 protein [21].
Therefore, the resulting concept on IDE as a potential
tumor suppressor protecting RB from inactivation by
insulin, as elaborated through structural [22-24] and
proteomic [25,26] studies, should remain an additional
important element to be further investigated in order to
better understand cancer promotion by insulin in the
years ahead. In this context, the following model may be
useful in guiding such upcoming efforts (Table 1).
In case the envisaged insulin-RB complexes and IDE
dysfunction will be validated in human cancer speci-
mens, this would then suggest as an antineoplastic treat-
ment strategy the interference with such intracellular
carcinogenesis by means of cell-penetrating peptides
that bind and thereby neutralize insulin such as those
peptides derived from RB and termed MCR peptides
[11,13,27-30].
Competing interests
The author declares having no competing interests.
Received: 25 January 2011 Accepted: 1 April 2011
Published: 1 April 2011
References
1. Gey GO, Thalhimer W: Observations of the effects of insulin introduced
into the medium of tissue cultures. JAMA 1924, 82:1609.
2. Salter J, Best CH: Insulin as a growth hormone. Br Med J 1953, 2:353-356.
3. Messina JL: Insulin as a growth-promoting hormone. In Handbook of
Physiology. Volume V. Hormonal Control of Growth, Oxford University Press;
1999:783-811.
4. Ullrich A, Bell JR, Chen EY, et al: Human insulin receptor and its
relationship to the tyrosine kinase family of oncogenes. Nature 1985,
313:756-761.
5. Rosen OM: After insulin binds. Science 1987, 237:1452-1458.
6. Goldfine ID, Smith GJ, Wong KY, Jones AL: Cellular uptake and nuclear
binding of insulin in human cultured lymphocytes: evidence for
potential intracellular sites of insulin action. Proc Natl Acad Sci USA 1977,
74:1368-1372.
7. Miller DS: Stimulation of RNA and protein synthesis by intracellular
insulin. Science 1988, 240:506-509.
8. Lin YJ, Harada S, Loten EG, Smith RM, Jarett L: Direct stimulation of
immediate-early genes by intranuclear insulin in trypsin-treated H35
hepatoma cells. Proc Natl Acad Sci USA 1992, 89:9691-9694.
9. Radulescu RT, Wendtner CM: Proposed interaction between insulin and
retinoblastoma protein. J Mol Recognit 1992, 5:133-137.
10. Radulescu RT, Bellitti MR, Ruvo M, Cassani G, Fassina G: Binding of the
LXCXE insulin motif to a hexapeptide derived from retinoblastoma
protein. Biochem Biophys Res Commun 1995, 206:97-102.
11. Radulescu RT, Doklea E, Kehe K, Mückter H: Nuclear colocalization and
complex formation of insulin with retinoblastoma protein in HepG2
human hepatoma cells. J Endocrinol 2000, 166:R1-R4.
12. Radulescu RT, Schulze J: Insulin-retinoblastoma protein (RB) complex
further revealed: intracellular RB is recognized by agarose-coupled
insulin and co-immunoprecipitated by an anti-insulin antibody. Logical
Biol 2002, 2:2-10.
13. Radulescu RT, Kehe K: Antiproliferative MCR peptides block physical
interaction of insulin with retinoblastoma protein (RB) in human lung
cancer cells. arXiv 2007 [http://arxiv.org/abs/0706.1991], 0706.1991v1
[q-bio.SC].
14. Chappell J, Leitner JW, Solomon , Golovchenko I, Goalstone ML, Draznin B:
Effect of insulin on cell cycle progression in MCF-7 breast cancer cells.
J Biol Chem 2001, 276:38023-38028.
15. Sears RC, Nevins JR: Signaling networks that link cell proliferation and
cell fate. J Biol Chem 2002, 277:11617-11620.
16. Castro A, Ziegels-Weissman J, Buschbaum P, Voigt W, Morales A, Nadji M:
Immunochemical demonstration of immunoreactive insulin in human
breast cancer. Res Commun Chem Pathol Pharmacol 1980, 29:171-182.
17. Spring-Mills EJ, Stearns SB, Numann PJ, Smith PH: Immunocytochemical
localization of insulin- and somatostatin-like material in human breast
tumors. Life Sci 1984, 35:185-190.
Table 1 The “IDE switch”: a) surges (particularly those of a pathological nature) in the extracellular/blood level of
insulin and b) defects in the activity of intracellular IDE are functionally equivalent to one another in that they both
lead to an increase in intracellular insulin, the former through augmented insulin internalization [31] and the latter
through decreased insulin degradation
Extracellular/blood insulin Intracellular IDE activity Intracellular insulin Intracellular insulin-RB heterodimers Cell proliferation
Normal Normal Minimal Minimal Normal
Increased* Normal Increased Increased Increased
Normal/Increased* Defective Increased Increased Increased
*i.e. hyperinsulinemia.
As a result, elevated intracellular insulin stimulates cell proliferation by binding and thereby inactivating the RB tumor suppressor, both in neoplastic diseases and
in aging-related morbidities such as Syndrome X or, respectively, the metabolic syndrome which includes various clinical manifestations such as
hyperinsulinemia, insulin resistance, obesity, type 2 diabetes and hypertension [32]. Interestingly, this model is supported by experimental data revealing
increased intracellular insulin concentrations in monocytes from obese patients and obese diabetic patients vs. those from normal subjects [33].
Radulescu Diabetology & Metabolic Syndrome 2011, 3:5
http://www.dmsjournal.com/content/3/1/5
Page 2 of 3
18. Radulescu RT, Hufnagel C, Luppa P, et al: Immunohistochemical
demonstration of the zinc metalloprotease insulin-degrading enzyme in
normal and malignant human breast: correlation with tissue insulin
levels. Int J Oncol 2007, 30:73-80.
19. Mattarocci S, Abbruzzese C, Mileo AM, et al: Intracellular presence of
insulin and its phosphorylated receptor in non-small cell lung cancer.
J Cell Physiol 2009, 221:766-770.
20. Harada S, Smith RM, Smith JA, Jarett L: Inhibition of insulin-degrading
enzyme increases translocation of insulin to the nucleus in H35 rat
hepatoma cells: evidence of a cytosolic pathway. Endocrinology 1993,
132:2293-2298.
21. Hainaut P, Milner J: A structural role for metal ions in the “wild-type”
conformation of the tumor suppressor protein p53. Cancer Res 1993,
53:1739-1742.
22. Radulescu RT: unpublished observation 1994.
23. Radulescu RT: Zinc-binding motif similarity between retinoblastoma
protein (RB) and insulin-degrading enzyme (IDE): insulin degradation as
a potential tumor suppression principle. Logical Biol 2005, 5:3-6.
24. Radulescu RT: Tumor suppressor and anti-inflammatory protein: an
expanded view on insulin-degrading enzyme (IDE). arXiv 2008
[http://arXiv.org/abs/0812.0160], 0812.0160v1 [q-bio.BM].
25. Radulescu RT, Poznic M, Pavelic K: Complex formation between metabolic
enzymes in tumor cells: unfolding the MDR1-IDE paradigm. Mol Cancer
Ther 2009, 8:3171.
26. Radulescu RT, Duckworth WC, Levy JL, Fawcett J: Retinoblastoma protein
co-purifies with proteasomal insulin-degrading enzyme: implications for
cell proliferation control. Biochem Biophys Res Commun 2010, 395:196-199.
27. Radulescu RT, Jaques G: Selective inhibition of human lung cancer cell
growth by peptides derived from retinoblastoma protein. Biochem
Biophys Res Commun 2000, 267:71-76.
28. Radulescu RT, Jaques G: Potent in vivo antineoplastic activity of MCR
peptides MCR-4 and MCR-14 against chemotherapy-resistant human
small cell lung cancer. Drugs Exp Clin Res 2003, 29:69-74.
29. Radulescu RT: Going beyond the genetic view of cancer. Proc Natl Acad
Sci USA 2008, 105:E12.
30. Radulescu RT, Fahraeus R: Targeting the RB pathway for cancer therapy:
peptide mimetic foundations and promise. Am J Transl Res 2010, 2:209.
31. Smith RM, Jarett L: Partial characaterization of mechanism of insulin
accumulation in H35 hepatoma cell nuclei. Diabetes 1990, 39:683-689.
32. Radulescu RT: Insulin-RB heterodimer: potential involvement in the
linkage between aging and cancer. Logical Biol 2006, 6:81-83.
33. Benzi L, Ciccarone AM, Cecchetti P, et al: Intracellular hyperinsulinism: a
metabolic characteristic of obesity with and without type 2 diabetes:
intracellular insulin in obesity and Type 2 diabetes. Diabetes Res Clin Pract
1999, 46:231-237.
doi:10.1186/1758-5996-3-5
Cite this article as: Radulescu: Intracellular insulin in human tumors:
examples and implications. Diabetology & Metabolic Syndrome 2011 3:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Radulescu Diabetology & Metabolic Syndrome 2011, 3:5
http://www.dmsjournal.com/content/3/1/5
Page 3 of 3
